Mirae Asset Global Investments
SEEL

Mirae Asset Global Investments’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Mirae Asset Global Investments’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,373
Closed -$422K – 2683
2023
Q4 		$422K Buy
2,373
+2,139
+914% +$1.05M ﹤0.01% 2044
2023
Q3 		$166K Sell
234
-33
-12% -$141K ﹤0.01% 2354
2023
Q2 		$1.23M Sell
267
-109
-29% -$378K ﹤0.01% 1451
2023
Q1 		$998K Buy
376
+55
+17% +$161K ﹤0.01% 1548
2022
Q4 		$837K Sell
321
-137
-30% -$478K ﹤0.01% 1587
2022
Q3 		$1.81M Sell
458
-213
-32% -$838K ﹤0.01% 1179
2022
Q2 		$1.75M Buy
671
+167
+33% +$435K ﹤0.01% 1179
2022
Q1 		$1.62M Buy
504
+135
+37% +$581K ﹤0.01% 1212
2021
Q4 		$2.31M Sell
369
-11
-3% -$84.5K ﹤0.01% 1089
2021
Q3 		$3.52M Sell
380
-2
-0.5% -$17.2K 0.01% 951
2021
Q2 		$3.88M Sell
382
-110
-22% -$1.81M 0.01% 879
2021
Q1 		$9.43M Buy
+492
New +$5.74M 0.03% 543

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

Mirae Asset Global Investments's SEEL Position: Q1 2024 in Review

Mirae Asset Global Investments sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 2,373 shares — an estimated $422K sold.

Mirae Asset Global Investments first reported a position in SEEL in Q1 2021 and held it in 12 quarters. The position peaked at $9.43M in Q1 2021. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • Mirae Asset Global Investments reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,373 Seelos Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $422K.
  • Mirae Asset Global Investments first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
  • Mirae Asset Global Investments's Seelos Therapeutics, Inc. Common Stock position peaked at $9.43M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Mirae Asset Global Investments's 13F filing for Q1 2024, filed 1 May 2024.